A study published in PMC on oxidative stress in Graves' disease found that: *Hyperthyroidism is associated with increased lipid peroxidation products in thyroid and liver tissue *Glutathione peroxidase activity is upregulated in an attempt to compensate for increased ROS generation - but this compensatory response is often insufficient, leading to net oxidative damage *Antioxidant treatment may help counter some of the clinical manifestations of thyrotoxicosis by reducing ROS-driven cellular damage A review in PMC on oxidative stress in Graves' disease concluded: "These data suggest that increased ROS generation may contribute to generate some clinical manifestations of thyrotoxicosis and that antioxidant treatment may be beneficial." Selenium supplementation - acting through GPx and the glutathione system - has been shown to delay disease progression and improve quality of life in patients with Graves' orbitopathy (the eye complication of Graves' disease), as confirmed by the Frontiers in Endocrinology review
But microdosing isnt something to try on your own
Ghio S, Scelsi L, Latini R, Masson S, Eleuteri E, Palvarini M, Vriz O, Pasotti M, Gorini M, Marchioli R, Maggioni A, Tavazzi L
The ARRIVE 2.0 checklist (Animal Research: Reporting of In Vivo Experiments) has become standard for any publication and covers 21 items (design, sample size, randomisation, blinding, statistics, ethics)
Springer, Berlin, Heidelberg, pp 133173 Stagner JI, Samols E, Marks V (1989) The anterograde and retrograde infusion of glucagon antibodies suggests that A cells are vascularly perfused before D cells within the rat islet
It is considered safe if used as directed and in small increments
